TrialJournal of hematology & oncology2016

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.

Yongkun Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.